Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

Table 3 Treatment regimen variations in the intraperitoneal therapy, either in the neoadjuvant or adjuvant n (%)

Treatment regimens	Total, n = 38	Adjuvant group, n = 25	Neoadjuvant group, n = 13
Taxol 175 mg/m2, Carboplatin AUC 5 or 6 every 3 wk	21 (55.3)	14 (56)	7 (54)
Carboplatin AUC 5 or 6, Taxol 80 mg/m2 day 1, 8, 15 every 3 wk (dose dense)	3 (7.9)	2 (8)	1 (8)1
Taxol 80 mg/m2 day 1, 8, Carboplatin AUC 2 day 1, 8 every 3 wk (weekly regimen)	1 (2.6)	0 (0)	1 (8)
Carboplatin AUC 5 and Docetaxel 75 mg/m2 every 3 wk	2 (5.2)	1 (4)	1 (8)
Carboplatin AUC 5 Gemcitabine 800 mg/m2 day 1, 8 every 3 wk (due to peripheral neuropathy)	1 (2.6)	1 (4)	0 (0)
Carboplatin AUC 5 or 6, Abraxane D1, 8 every 3 wk (due to allergic reaction to Taxel)	3 (7.9)	1 (4)	2 (15)
Carboplatin AUC with Taxol x1, with Docetaxel x1 and with Gemcitabine x1 (due to allergic reaction)	1 (2.6)	1 (4)	0 (0)
No IV treatment, IP treatment only	6 (15.8)	5 (20)	1 (8)
Completion of ≥ 6 cycles of IV + IP treatment	34 (89.5)	22 (88)	12 (92)
Completion of 7-10 cycles of IV + IP	5 (13.1)	2 (8)	3 (23)
Subsequent treatment with Bevacizumab at progression	19 (50)	13 (52)	6 (46)

¹This patient also received Bevacizumab with dose dense regimen in the neoadjuvant period. IP: Intraperitoneal; IV: Intravenous.